In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight (NEJM)
Diabetes News
Category: Obesity
Associations between serum total bilirubin, obesity and type 2 diabetes
This study suggests that STB is associated with an elevated risk of T2D. More importantly, we reported for the first time that BMI may moderate the association between bilirubin and T2D (Diabetology & Metabolic Syndrome)
Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity
The STEP 5 trial demonstrated an average weight loss of 15.2% with Wegovy™ at 104-weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with placebo (Novo Nordisk)
The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors
A modest BW loss of 0–5% associated with SGLT2i treatment was associated with a favorable renal outcome. Caution should be taken for whom are underweight at baseline or have a pronounced BW loss ≥ 10.0% associated with SGLT2i treatment, which was associated with a worse renal outcome (Cardiovascular Diabetology)
Metformin for pediatric obesity and insulin resistance: a retrospective study within an integrated health care system
Metformin with lifestyle interventions significantly reduced weight, BMI, and BMI z score in pediatric patients with obesity and insulin resistance up to 24 months, compared with intensive and routine counseling alone (Obesity)
Semaglutide’s Success Could Usher in a “New Dawn” for Obesity Treatment
Despite obesity specialists’ enthusiasm for the drug’s potential, they also described major barriers to uptake and accessibility. Those barriers, they say, are rooted in the sordid legacy of weight-loss drugs and outdated notions of obesity (JAMA)
Gut microbiota changes after metabolic surgery in adult diabetic patients with mild obesity: a randomised controlled trial
This was the first RCT studying composite clinical, analytic, and microbiome changes in T2DM patients with class 1 obesity after RYGB versus standard medical therapy. The remarkable phenotypic improvement after surgery occurred concomitantly with changes in the gut microbiome, but at a lower level (Diabetology & Metabolic Syndrome)
Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges
This review, by gathering current evidence, highlights the need of solid knowledge in all facets of the treatment of patients with obesity and T1D that can only be obtained through high quality well-designed studies (Diabetes, Metabolic Syndrome and Obesity)
Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study
We aimed to prospectively identify ethnicity-specific BMI cutoffs for obesity based on the risk of type 2 diabetes that are risk-equivalent to the BMI cutoff for obesity among White populations (≥30 kg/m2). (Lancet)
Reducing weight and BMI following gestational diabetes: a systematic review and meta-analysis of digital and telemedicine interventions
In summary, this systematic review demonstrated the point estimate of the effect of the intervention on weight and BMI has potential to be clinically relevant but was not statistically significant (BMJ Open, Diabetes Research & Care)
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
Among adults with overweight or obesity who completed a 20-week run-in period with subcutaneous semaglutide, 2.4 mg once weekly, maintaining treatment with semaglutide compared with switching to placebo resulted in continued weight loss over the following 48 weeks (JAMA)
Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis
Nearly a quarter of the type 1 diabetes mellitus patients were affected by metabolic syndrome. Therefore, more attention should be paid to the prevention and control of the epidemic and for the reduction of the morbidity and mortality associated with metabolic syndrome among type 1 diabetes mellitus patients (Diabetes and Metabolic Syndrome)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight (NEJM)
Insulin-Stimulated Muscle Glucose Uptake and Insulin Signaling in Lean and Obese Humans
We suggest that reduced muscle glucose uptake in obesity is not due to defects in the insulin signaling pathway at the level of Akt/AS160, which suggests there remain significnt gaps in our knowledge of muscle insulin resistance in obesity. Our data imply that models of acute lipotoxicity don’t replicate the pathophysiology of obesity (Journal of Clinical Endocrinology & Metabolism)
Durability of glycaemic control in type 2 diabetes: A systematic review and meta‐analysis for its association with body weight changes
Modest weight loss with a goal of 2‐3% of body weight should be recommended to improve therapeutic durability and prevent beta‐cell deterioration (Diabetes, Obesity and Metabolism)
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy (NEJM)
Time Course of Normalization of Functional β-Cell Capacity in the Diabetes Remission Clinical Trial After Weight Loss in Type 2 Diabetes
A gradual increase in assessed functional β-cell capacity occurred after weight loss, becoming similar to that of NDC group participants by 12 months. This result was unchanged at 2 years with continuing remission of type 2 diabetes (Diabetes Care)
Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study
Among persons with weight loss of at least 5% after 1 year, those originally randomly assigned to metformin had the greatest loss during years 6 to 15. Older age and the amount of weight initially lost were the most consistent predictors of LTWL maintenance (Annals of Internal Medicine)
Adiposity and Diabetes Risk in Adults with Prediabetes: Heterogeneity of Findings Depending on Age and Anthropometric Measure
The association of central adiposity with type 2 diabetes incidence was lower for people in the older age group than for those in the younger age group (Obesity)
Uptake and retention in group-based weight-management services
Literature review and behavioural analysis (Public Health England)
- 1
- 2
- 3
- …
- 5
- Next Page »
Glycosmedia is also available as an App: